Abstract
The efficacy of Rivaroxaban («Xarelto®») for preventing venous thromboembolism during the early postoperative period and outpatient treatment stage in patients after hip joint (70 cases) and knee joint (30 cases) arthroplasty, as well as intramedullary osteosynthesis (150 cases) for fractures of long bones of extremities, was assessed. The drug was used at a dose of 10 mg once a day, starting from 6–10 hours after the operation and up to 35 days. A high efficacy and safety of Rivaroxaban («Xarelto®») was revealed. An allergic response was registered in one patient.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
